Single-case study of a secondary interdigitating dendritic cells sarcoma highlights the role of RAS mutation in trans-differentiation phenomenon and uncovers a potential efficacy of anti-CD19 CAR-T cell therapy

Related Experiment Video

Updated: Jun 23, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.4K

Imane Karrat1,2, Côme Sesboue3, Audrey Gros4

  • 1CHU de Bordeaux, Service d'hématologie Clinique et de thérapie cellulaire, Bordeaux, France.

Leukemia & Lymphoma
|November 13, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.3K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.4K

Related Experiment Videos

Last Updated: Jun 23, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.4K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.3K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.4K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

Articles linked to this work by shared authors, journal, and citation graph.

A European study on blood mutation monitoring in children with BRAFV600E-positive Langerhans Cell Histiocytosis.

Blood advances·2026

ACUTE DEFEROXAMINE-INDUCED RETINOPATHY.

Retinal cases & brief reports·2026

Phenotype, treatment, and determinants of prognosis in Erdheim-Chester disease: an international, retrospective, cohort study.

The Lancet. Haematology·2026

MEK inhibition achieves robust and durable responses in Erdheim-Chester disease.

HemaSphere·2026

BEAM versus EAM, FEAM, BeEAM, and TEAM: exploring conditioning strategies in autologous stem cell transplantation for Hodgkin lymphoma a retrospective study of the LWP of EBMT.

Bone marrow transplantation·2026

Contemporary Treatment and Survival Outcomes in Mantle Cell Lymphoma: A National Real-World Analysis From REALYSA, a LYSA Cohort.

Hematological oncology·2026

The APLC 2025 consensus recommendations on the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia.

Leukemia & lymphoma·2026

Lower baseline eosinophil counts are associated with inferior survival in Mantle cell lymphoma.

Leukemia & lymphoma·2026

Single-Cell RNA sequencing analysis of cellular heterogeneity and microenvironment-driven signaling networks in acute myeloid leukemia.

Leukemia & lymphoma·2026

Patients' preferences for accepting risks and uncertainty in AML treatments within European public health care systems: a cross-sectional study in Finland, Italy, and Germany.

Leukemia & lymphoma·2026

Time burden and treatment patterns of patients with newly diagnosed acute myeloid leukemia receiving parenteral hypomethylating agents in combination with venetoclax.

Leukemia & lymphoma·2026

Care pathway of patients with second-line large B-cell lymphoma treated with CAR T-cell therapies in France.

Leukemia & lymphoma·2026

Testosterone treatment prevents most gonadectomy-induced metabolic and skeletal deficiencies in female mice.

Frontiers in endocrinology·2026

Metabolic oncology: clonal selection and the pre-existing origins of cancer resistance.

Frontiers in oncology·2026

Comparative efficacy of fruquintinib, regorafenib or TAS-102 in patients with KRAS-mutant metastatic colorectal cancer: a systematic review and network meta-analysis.

Frontiers in oncology·2026

Rutin interferes with hnRNP L phase separation and modulates the PKM2-lactate-H3K9la axis in pulmonary fibrosis.

Frontiers in pharmacology·2026

PROTAC-DB 4.0: an expanded knowledgebase of targeted protein degradation modalities with AI-powered knowledge discovery.

Nucleic acids research·2026

Single-Nucleus Transcriptomics Reveal Mechanisms of Cardiovascular Protection Against Ponatinib-Induced Cardiotoxicity Through ROCKs Deletion in Cardiomyocytes.

Archivum immunologiae et therapiae experimentalis·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us